News

Aubagio did not receive positive opinion from the committee concerning new active substance (NAS) designation. Genzyme CEO and president David Meeker said the positive CHMP opinion and broad

Simcere Pharmaceutical holds 52.5% equity interest in Simcere Vaxtec subsidiary that expects to resume influenza vaccine production. Separately, the company also announced the resignation of executive vice president

The bi-axial agitation properties of XRS 20 Bioreactor System accelerate nutrient and metabolite transport in the cellular micro-environment through improved mixing and higher mass transfer. Thus, the cultures

TOBI Podhaler is new non-nebulized formulation and delivery system of tobramycin that is indicated for CF patients with Pseudomonas aeruginosa (Pa) bacteria in the lungs. The first dry

Probuphine is a long-acting, subdermal implant formulation of buprenorphine for the maintenance treatment of adult patients with opioid dependence. Titan Pharmaceuticals executive vice president and chief development officer

The sanction involves the temporary suspension of Takeda’s activities as vice president of the JPMA for the period of six months starting from 21March 2013. In December 2012

The Holding Incubator Green Chemistry, which has invested € 0.5m, will hold 51% of Deinobiotics while Deinove 49%. Deinove CEO Emmanuel Petiot said, "Our priority at DEINOVE is

The legal action, initiated by Dr. Reddy’s in New Jersey, related to certain bioequivalence studies by the former MDS Pharma Services business unit from 1 January 2000 to

The Duke clinical research unit is the early phase unit of the Duke Clinical Research Institute. Benitec chief executive officer Peter French said, "The TT-034 trial marks the